Basic Information
| Drug ID | DDPD00448 |
|
| Drug Name | Lansoprazole | |
| Molecular Weight | 369.361 | |
| Molecular Formula | C16H14F3N3O2S | |
| CAS Number | 103577-45-3 | |
| SMILES | CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 | |
| External Links | ||
| DRUGBANK | DB00448 | |
| PubChem Compound | 3883 | |
| PDR | 1930 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Melting Point | 180.0 | ℃ | 178-182 | ℃ | https://www.chemicalbook.com/ChemicalProductProperty_US_CB6396972.aspx |
| Water Solubility | 0.97 | mg/L | 0.97 | mg/L | FDA Label |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 85.0 | % | 80-90 | % | PO, oral; | DRUGBANK | Bioavailability | 81.0 | % | 81±22 | % | PO, oral; Male, men; normal,healthy; | The Pharmacological Basis of Therapeutics |
| C Max | 248.0 | ng/ml | 248±140 | ng/ml | Oral single dose; Male, men; normal,healthy; | The Pharmacological Basis of Therapeutics | |
| T Max | 1.7 | h | 1.7 | h | PO, oral; | DRUGBANK | T Max | 1.3 | h | 1.3±0.6 | h | Oral single dose; Male, men; normal,healthy; | The Pharmacological Basis of Therapeutics |
| Clearance | 30.0 | L/h | 400-600 | ml/min | DRUGBANK | Clearance | 0.37 | L/h/kg | 6.23±1.60 | ml/min/kg | Elderly ↓ ;severe hepatic impairment ↓ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.26 | L/h/kg | 4.4 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 0.40 | L/kg | 0.4 | L/kg | Apparent volume of distribution; | DRUGBANK | Volume of Distribution | 0.35 | L/kg | 0.35±0.05 | L/kg | The Pharmacological Basis of Therapeutics | Volume of Distribution | 0.28 | L/kg | 0.28 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 2.0 | h | <=2 | h | DRUGBANK | Half-life | 0.90 | h | 0.9±0.44 | h | normal,healthy; Male, men; | chronic liver disease ↑ ;Hepatic cirrhosis, cirr → ;Age ↑ ; | The Pharmacological Basis of Therapeutics | Half-life | 1.0 | h | 1 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Eliminate Route | 18.5 | % | 14-23 | % | Urinary excretion; | DRUGBANK | Eliminate Route | 1.0 | % | <1 | % | Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 97.0 | % | 97 | % | plasma proteins; | DRUGBANK | Protein Binding | 97.0 | % | 97 | % | Male, men; normal,healthy; human, homo sapiens; | RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 1.5 | mg/kg/day | 1.5 | mg/kg/day | Prevacid | lansoprazole | PDR | |
| Max dose for infants | 2.0 | mg/kg/day | 2 | mg/kg/day | Prevacid | lansoprazole | PDR | |
| Max dose for children | 30.0 | mg/day | 30 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for children | 60.0 | mg/day | 60 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for children | 30.0 | mg/day | 30 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for children | 60.0 | mg/day | 60 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for children | 15.0 | mg/day | 15 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for children | 2.5 | mg/kg/day | 2.5 | mg/kg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for children | 60.0 | mg/day | 60 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for adolescents | 30.0 | mg/day | 30 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for adolescents | 60.0 | mg/day | 60 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for adults | 30.0 | mg/day | 30 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for adults | 90.0 | mg/day | 90 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for adults | 120.0 | mg/day | 120 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for adults | 180.0 | mg/day | 180 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for geriatric | 30.0 | mg/day | 30 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for geriatric | 90.0 | mg/day | 90 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for geriatric | 120.0 | mg/day | 120 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
| Max dose for geriatric | 180.0 | mg/day | 180 | mg/day | PO, oral | Prevacid | lansoprazole | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1